银屑病关节炎患者对药物共同决策看法的访谈研究
该研究对澳大利亚25例成人银屑病关节炎患者进行面对面半结构化访谈并作主题分析,描述其对药物共同决策的看法。识别出五个主题:决策中缺乏自主权、被潜在危害困扰、获得信心、选择替代方案、建立信任与强化协作。结论认为患者决策自主权不足且对系统性药物潜在危害感到不堪重负。
要点
- 患者在与医生共同决策时缺乏自主权,感到被否定选择且知识不对称。
- 对系统性药物副作用的恐惧及对生育、生活方式的担忧使决策负担沉重。
- 提升知识、信任与协作环境及风险管理策略可能改善药物决策。
核心结论
- 银屑病关节炎患者在药物治疗决策中缺乏自主权,并被系统性药物的潜在危害所困扰。
- 改善与医疗团队的知识和信任、提供支持性协作环境及风险管理策略可能改善药物决策。
研究设计与样本
- 对澳大利亚25例成人银屑病关节炎患者进行面对面半结构化访谈,并对转录文本进行主题分析。
主要发现
- 识别出五个主题:决策中缺乏自主权、被潜在危害困扰、获得信心、选择替代方案、建立信任与强化协作。
- 缺乏自主权包括被否定选择、知识不对称、绝望与必要性、不公平资格标准限制及自动化方式。
- 被潜在危害困扰包括对激进治疗的畏惧、预期副作用扰乱生活方式、危及生育与妊娠及避免复发。
临床怎么用
- 临床中应关注患者在药物决策中的自主权感受,并主动处理其对系统性药物潜在危害的担忧。
- 通过改善知识传递、建立信任和协作环境,以及提供风险与副作用管理策略来支持共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Decision-making regarding medications to manage psoriatic arthritis (PsA) is complex because of multiple disease manifestations and comorbidities. Fear of side effects from systemic medications and misalignment in priorities between patients with PsA and rheumatologists makes shared decision-making challenging. We aimed to describe the perspectives of patients with PsA on shared decision-making regarding medication taking. METHODS: Face-to-face semistructured interviews were conducted with 25 adult patients with PsA in Australia. Transcripts were thematically analyzed. RESULTS: Five themes were identified: lacking agency in decision-making (denied choice, knowledge asymmetry, desperation and necessity, restricted by unfair eligibility criteria, automated approach); overwhelmed by potential harms (daunted by aggressive therapy, anticipating lifestyle disruption from side effects, jeopardizing fertility and pregnancy, avoiding relapse); gaining confidence (discernible benefit in function and mental health, sharpening knowledge over time, expertise of family and peers, empowered by information); opting for alternatives (pursuing normality, suspicion of over-medicalization, seeking comprehensive solutions); and developing trust and fortifying collaboration (assurance through a personable approach, seeking consistency, supported in decisional power, resolution through respectful negotiation). CONCLUSION: Patients with PsA lack agency in making treatment decisions and are overwhelmed by the potential harms of systemic medication. Improving knowledge and trust with medical teams in a supportive and collaborative environment, and strategies for managing risks and side effects may improve decision-making about pharmacologic management of PsA.
引用
- Sumpton D, Oliffe M, Kane B, et al. Patients' Perspectives on Shared Decision-Making About Medications in Psoriatic Arthritis: An Interview Study. Arthritis Care Res (Hoboken). 2022. PMID: 34235887. doi:10.1002/acr.24748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。